证券日报网讯 12月2日晚间，安科生物发布公告称，本次申请解除限售的抗肿瘤事业部预留授予激励对 象共19名，申请解除限售的第一类限制性股票数量为372，750股，占公司目前股本总额1，672，521， 258股的0.0223%，本次解除限售的限制性股票上市流通日为2025年12月5日。 （文章来源：证券日报） ...

证券代码：300009 证券简称：安科生物 公告编号：2025-073 安徽安科生物工程(集团)股份有限公司 关于第三期限制性股票激励计划抗肿瘤事业部获授人员预留授予 股票第一个解除限售期解除限售股份上市流通的提示性公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 重要内容提示： 安徽安科生物工程（集团）股份有限公司（以下简称"公司"） 于 2025 年 11 月 24 日召开了第八届董事会第二十四次会议、第八届监事会第二十二次会议，审 议通过了《关于第三期限制性股票激励计划抗肿瘤事业部获授人员首次授予股票第 一个解除限售期解除限售条件成就及预留授予股票第一个解除限售期解除限售条 件部分成就的议案》，同意按照《公司第三期限制性股票激励计划（草案修订稿）》 （以下简称"《第三期激励计划》"）的相关规定以及公司 2022 年第二次临时股 东大会的授权，对满足解除限售条件的激励对象办理解除限售事宜。本次解除限售 的具体情况如下： 一、第三期激励计划实施情况简述 1、2022 年 8 月 24 日，公司召开第七届董事会第二十二次会议及第七届监事会 第十九次会议，审议通 ...

证券代码：300009 证券简称：安科生物 公告编号：2025-071 安徽安科生物工程(集团)股份有限公司 关于第三期限制性股票激励计划抗肿瘤事业部以外获授人员首次 授予股票第三个解除限售期解除限售股份上市流通的提示性公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 重要内容提示： 安徽安科生物工程（集团）股份有限公司（以下简称"公司"）于 2025 年 11 月 24 日召开了第八届董事会第二十四次会议、第八届监事会第二十二次会议，审 议通过了《关于第三期限制性股票激励计划抗肿瘤事业部以外获授人员首次授予股 票第三个解除限售期解除限售条件成就的议案》，同意按照《公司第三期限制性股 票激励计划（草案修订稿）》（以下简称"《第三期激励计划》"）的相关规定以及公 司 2022 年第二次临时股东大会的授权，对满足解除限售条件的激励对象办理解除 限售事宜。本次解除限售的具体情况如下： 一、第三期激励计划实施情况简述 1、2022 年 8 月 24 日，公司召开第七届董事会第二十二次会议及第七届监事会 第十九次会议，审议通过了《关于<公司第三期限制性股票激励计划（草案 ...

证券代码：300009 证券简称：安科生物 公告编号：2025-072 安徽安科生物工程(集团)股份有限公司 关于第三期限制性股票激励计划抗肿瘤事业部获授人员首次授予 股票第一个解除限售期解除限售股份上市流通的提示性公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 重要内容提示： 安徽安科生物工程（集团）股份有限公司（以下简称"公司"） 于 2025 年 11 月 24 日召开了第八届董事会第二十四次会议、第八届监事会第二十二次会议，审 议通过了《关于第三期限制性股票激励计划抗肿瘤事业部获授人员首次授予股票第 一个解除限售期解除限售条件成就及预留授予股票第一个解除限售期解除限售条 件部分成就的议案》，同意按照《公司第三期限制性股票激励计划（草案修订稿）》 （以下简称"《第三期激励计划》"）的相关规定以及公司 2022 年第二次临时股 东大会的授权，对满足解除限售条件的激励对象办理解除限售事宜。本次解除限售 的具体情况如下： 一、第三期激励计划实施情况简述 1、2022 年 8 月 24 日，公司召开第七届董事会第二十二次会议及第七届监事会 第十九次会议，审议通 ...

Company Overview - Baoji Pharmaceutical is set to launch an IPO from December 2 to December 5, 2025, offering 37.9117 million shares, with 10% allocated for Hong Kong and 90% for international sales. The maximum public offering price is HKD 26.38 per share, with an entry fee of approximately HKD 2,664, and shares are expected to begin trading on December 10, 2025 [1] - The company has attracted significant investment, with a total funding exceeding CNY 1.5 billion from various investors, including local industry capital and market-oriented funds, resulting in a post-investment valuation of approximately CNY 4.87 billion, which is 23 times the initial post-investment valuation [1] Investment and Partnerships - The IPO has secured a strong cornerstone investor lineup, including well-known institutions such as Anke Bio, DC Alpha SPC, and Guotai Junan Securities, with a total subscription of HKD 200.6 million, accounting for about 21.77% of the total fundraising [2] - The presence of cornerstone investors highlights market recognition of the company's technological capabilities and commercial potential, providing a solid foundation for the smooth progress of the issuance [2] Product Pipeline and Technology - Baoji Pharmaceutical focuses on four key areas: antibody-mediated autoimmune diseases, large-volume subcutaneous injections, reproductive medicine drugs, and transformative products replacing traditional biochemical extraction methods. The company has developed a robust pipeline with seven clinical-stage candidates and seven preclinical candidates [2] - The core pipeline includes KJ017, a recombinant hyaluronidase for large-volume subcutaneous delivery, which is currently under review for market approval; KJ103, an IgG degrading enzyme in Phase III clinical trials for autoimmune diseases; and SJ02, the first long-acting follicle-stimulating hormone approved in China, which received approval in August [3] Commercialization and Market Position - The commercialization of the hyaluronidase technology has led to partnerships with several antibody drug companies, and an exclusive sales agency agreement with Anke Bio for SJ02 in Greater China has been established [3] - The focus on large-volume subcutaneous injection technology positions Baoji Pharmaceutical as a key player in the biopharmaceutical sector, offering advantages over traditional intravenous administration by reducing adverse events and significantly shortening administration time from 30-180 minutes to 2-5 minutes [3] Industry Landscape - Halozyme is identified as a leading company in the global hyaluronidase subcutaneous injection technology, with its technology applied to several major antibody drugs. The trend of developing subcutaneous versions of various drugs, including oncology treatments, is gaining momentum [4] - Baoji Pharmaceutical aims to become the "Halozyme of China," leveraging its expertise in hyaluronidase technology and core pipeline to empower its products and assist other domestic antibody drugs in achieving subcutaneous delivery upgrades, thereby capturing a significant market position in the biopharmaceutical innovation wave [4]

Group 1 - The company, Baoji Pharmaceutical-B (02659.HK), plans to globally offer 37.9117 million H-shares, with 3.7912 million shares available in Hong Kong and 34.1205 million shares for international distribution, subject to reallocation [1] - The offering price is set at HKD 26.38 per share, with a trading unit of 100 shares, and the shares are expected to commence trading on the Hong Kong Stock Exchange on December 10, 2025 [1] Group 2 - The company, established in 2019, focuses on four strategic areas: large-volume subcutaneous delivery, antibody-mediated autoimmune diseases, assisted reproduction, and recombinant biopharmaceuticals [2] - The pipeline includes 12 self-developed products, with three core products: SJ02 (a long-acting recombinant human follicle-stimulating hormone), KJ017 (a recombinant hyaluronidase), and KJ103 (an innovative recombinant immunoglobulin G degrading enzyme) [2] Group 3 - The company has entered into cornerstone investment agreements, with cornerstone investors agreeing to subscribe for shares totaling HKD 200.6 million, which equates to approximately 7.6041 million shares at the offering price [3] - The net proceeds from the global offering are expected to be approximately HKD 921.5 million, with allocations of 53.5% for R&D and commercialization of core products, 17.7% for advancing other pipeline products, 8.4% for optimizing the proprietary synthetic biology platform, 10.4% for enhancing production capacity, and 10.0% for working capital and general corporate purposes [3]

Company Overview - Baoji Pharmaceutical-B (02659) plans to conduct an IPO from December 2 to December 5, 2025, offering 37.9117 million shares, with 10% allocated for Hong Kong and 90% for international sales. The maximum public offering price is set at HKD 26.38 per share, with an entry fee of approximately HKD 2,664 [1] - The company has attracted significant investment, with total funding exceeding CNY 1.5 billion from various investors, including local industry capital and market-oriented funds, resulting in a post-investment valuation of approximately CNY 4.87 billion, which is 23 times the initial post-investment valuation [1] Investment and Partnerships - The IPO has secured a strong cornerstone investor lineup, including notable institutions such as Anke Bio Hong Kong and Guotai Junan Securities, with a total subscription of HKD 200.6 million, accounting for about 21.77% of the total fundraising [2] - The company has established a comprehensive pipeline with 7 clinical-stage candidates and 7 preclinical candidates, focusing on areas such as antibody-mediated autoimmune diseases and large-volume subcutaneous injections [2] Product Pipeline - The core pipeline includes KJ017, a recombinant hyaluronidase for large-volume subcutaneous delivery, currently under review for market approval; KJ103, an IgG-degrading enzyme in Phase III clinical trials for autoimmune diseases; and SJ02, the first long-acting follicle-stimulating hormone approved in China, which received approval in August [3] - The commercialization of the hyaluronidase technology has led to agreements with several antibody drug companies, and a unique sales agency agreement with Anke Bio for SJ02 in Greater China [3] Industry Positioning - Baoji Pharmaceutical is positioned to become a Chinese counterpart to Halozyme, leveraging its hyaluronidase technology to enhance the commercialization of its pipeline products and assist other domestic antibody drugs in achieving subcutaneous delivery upgrades [4] - The industry is witnessing a shift towards subcutaneous administration, with major companies like Merck and Daiichi Sankyo developing subcutaneous versions of their drugs, indicating a growing trend in the biopharmaceutical sector [4]

Core Viewpoint - The stock price of Weisheng Pharmaceutical-B (02561) has seen a significant increase, rising over 7% during trading and currently up by 3.64% to HKD 31.88, driven by positive news regarding its collaboration with Anke Bio [1] Group 1: Company Developments - Anke Bio (300009) has recently disclosed progress in its collaboration with Weisheng Pharmaceutical, specifically regarding the approval of Longpei Growth Hormone [1] - On July 14, Anke Bio announced the signing of a strategic cooperation framework agreement with Weisheng Pharmaceutical to promote the Longpei Growth Hormone in the Chinese market [1] - Weisheng Pharmaceutical's core product, Longpei Growth Hormone, had its application for market approval accepted by the National Medical Products Administration of China in March 2024, with expectations for approval in the second half of 2025 [1]

Core Insights - The company is focusing on maintaining stable growth in its traditional business while expanding into innovative drug development, particularly in the field of growth hormones and fertility treatments [6][7]. Group 1: Sales Strategy and Market Positioning - The company plans to leverage its established marketing team and extensive hospital coverage to ensure steady sales growth in growth hormones, despite a decline in newborn numbers [2]. - The collaboration with Weisheng Pharmaceutical for the long-acting growth hormone, Longpei, is positioned as a high-quality product with a unique market advantage due to its clinical validation [3]. - The company is actively promoting its long-acting follicle-stimulating hormone, Shengnuowa, through various sales channels, including private hospitals, which are not restricted by regulatory hurdles [4]. Group 2: Research and Development Progress - The company is advancing its dual-target Her2 and PD-L1*4-1BB dual antibody drugs, with plans for non-clinical research and IND application in the coming years [5]. - The establishment of the Anke Biological Innovation Research Institute aims to attract top talent and enhance R&D capabilities to overcome current research bottlenecks [6][7]. Group 3: Financial Performance - For the first three quarters of 2025, the company reported a main revenue of 1.963 billion yuan, a year-on-year increase of 2.15%, while net profit decreased by 6.48% to 551 million yuan [8]. - The third quarter alone saw a revenue of 670 million yuan, reflecting a 7.7% year-on-year increase, with net profit rising by 6.56% to 185 million yuan [8].

Group 1: Company Overview and Leadership - Anke Bioengineering has strategic partnerships with companies like Boshengji, Afana, and Yuansong Bio, focusing on innovative drug development and commercialization [3][4][5][6] - The leadership team includes Chairman and President Song Lihua, Vice Chairman Zhou Yuanyuan, and several vice presidents overseeing various departments [2][3] Group 2: Research and Development Highlights - Boshengji's CAR-T PA3-17 has entered critical clinical trial phases, aiming for full patient enrollment by Q1 2027 and pre-NDA communication submission [3] - Yuansong Bio's lead product, recombinant L-IFN adenovirus injection, has progressed to Phase IIa clinical trials in China [5] - Afana has received clinical trial approvals for six Class I new drugs, focusing on autoimmune diseases and mRNA therapies, with significant advancements in CAR-T and HPV treatments [6][7] Group 3: Product Pipeline and Market Strategy - The company is advancing a long-acting growth hormone, expected to be approved by the end of 2025, with a focus on leveraging its commercial capabilities [4][8] - The long-acting follicle-stimulating hormone has begun market entry, with ongoing efforts to establish partnerships with private hospitals for sales [9] - The dual-target Her2 and PD-L1*4-1BB antibodies are in clinical development, with plans for IND submission in 2027 [10][11] Group 4: Financial and Market Positioning - The company aims to maintain stable growth in its traditional business while expanding into innovative drug markets [11] - Strategic focus on optimizing product structure and enhancing market competitiveness through accelerated commercialization and R&D capabilities [11] - The company is developing a comprehensive 3, 5, and 10-year strategic plan to address market challenges and enhance its positioning in the capital market [11]